RU2018125003A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2018125003A3 RU2018125003A3 RU2018125003A RU2018125003A RU2018125003A3 RU 2018125003 A3 RU2018125003 A3 RU 2018125003A3 RU 2018125003 A RU2018125003 A RU 2018125003A RU 2018125003 A RU2018125003 A RU 2018125003A RU 2018125003 A3 RU2018125003 A3 RU 2018125003A3
- Authority
- RU
- Russia
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201511024618 | 2015-12-31 | ||
| CN201511024618.2 | 2015-12-31 | ||
| PCT/CN2016/111053 WO2017114230A1 (zh) | 2015-12-31 | 2016-12-20 | Pcsk9抗体、其抗原结合片段及其医药用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2018125003A RU2018125003A (ru) | 2020-02-03 |
| RU2018125003A3 true RU2018125003A3 (ru) | 2020-05-13 |
| RU2739208C2 RU2739208C2 (ru) | 2020-12-21 |
Family
ID=59224496
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018125003A RU2739208C2 (ru) | 2015-12-31 | 2016-12-20 | Анти-pcsk9 антитело, его антигенсвязывающий фрагмент и их медицинское применение |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10793643B2 (ru) |
| EP (1) | EP3398968B1 (ru) |
| JP (1) | JP7032662B2 (ru) |
| KR (1) | KR102767973B1 (ru) |
| CN (1) | CN107406511B (ru) |
| AU (1) | AU2016382932B2 (ru) |
| BR (1) | BR112018013256A2 (ru) |
| CA (1) | CA3009904A1 (ru) |
| MX (1) | MX2018007925A (ru) |
| RU (1) | RU2739208C2 (ru) |
| TW (1) | TWI735499B (ru) |
| WO (1) | WO2017114230A1 (ru) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3067953A1 (en) * | 2017-06-30 | 2019-01-03 | Jiangsu Hengrui Medicine Co., Ltd. | Pharmaceutical composition comprising pcsk-9 antibody and use thereof |
| CN110981962B (zh) * | 2019-12-19 | 2022-07-12 | 中国药科大学 | Pcsk9抗体、其抗原结合片段及其应用 |
| US20230108572A1 (en) * | 2020-03-19 | 2023-04-06 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Method For Treating Cholesterol-Related Diseases |
| CN114369164A (zh) * | 2020-10-15 | 2022-04-19 | 苏州君盟生物医药科技有限公司 | 抗pcsk9单克隆抗体的生产工艺 |
| EP4431528A1 (en) * | 2021-10-29 | 2024-09-18 | Longbio Pharma (Suzhou) Co., Ltd. | Isolated antigen binding protein and use thereof |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4116793A (en) | 1992-04-24 | 1993-11-29 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US7658921B2 (en) | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| CA2567253A1 (en) * | 2004-05-18 | 2005-11-24 | Silverbrook Research Pty Ltd | Pharmaceutical product tracking |
| US7572618B2 (en) * | 2006-06-30 | 2009-08-11 | Bristol-Myers Squibb Company | Polynucleotides encoding novel PCSK9 variants |
| JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
| AR070315A1 (es) * | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Anticuerpos 1b20 antagonistas de pcsk9 |
| TWI516501B (zh) * | 2008-09-12 | 2016-01-11 | 禮納特神經系統科學公司 | Pcsk9拮抗劑類 |
| JO3672B1 (ar) * | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| AR079336A1 (es) | 2009-12-11 | 2012-01-18 | Irm Llc | Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9) |
| CN105218674A (zh) | 2010-03-11 | 2016-01-06 | 瑞纳神经科学公司 | 呈pH依赖性抗原结合的抗体 |
| WO2012054438A1 (en) | 2010-10-22 | 2012-04-26 | Schering Corporation | Anti-pcsk9 |
| US20140121123A1 (en) | 2010-10-29 | 2014-05-01 | Kevin Caili Wang | Methods for diversifying antibodies, antibodies derived therefrom and uses thereof |
| US20120195910A1 (en) | 2010-12-22 | 2012-08-02 | Genentech, Inc. | Anti-pcsk9 antibodies and methods of use |
| BR112013018877A2 (pt) | 2011-01-28 | 2016-10-04 | Sanofi Sa | composições farmacêuticas que compreendem anticorpos humanos para pcsk9 |
| KR20140006022A (ko) | 2011-02-11 | 2014-01-15 | 아이알엠 엘엘씨 | Pcsk9 길항제 |
| JOP20200043A1 (ar) * | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
| WO2012170607A2 (en) | 2011-06-10 | 2012-12-13 | Novartis Ag | Use of pcsk9 antagonists |
| WO2012168491A1 (en) | 2011-06-10 | 2012-12-13 | Novartis Ag | Pharmaceutical formulations of pcsk9 antagonists |
| RU2576034C2 (ru) | 2011-07-14 | 2016-02-27 | Пфайзер Инк. | Лечение антителами против pcsk9 |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| WO2013039969A1 (en) | 2011-09-16 | 2013-03-21 | Regeneron Pharmaceuticals, Inc. | METHODS FOR REDUCING LIPOPROTEIN(a) LEVELS BY ADMINISTERING AN INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9) |
| AR087715A1 (es) | 2011-09-16 | 2014-04-09 | Lilly Co Eli | Anticuerpos anti pcsk9 y usos de los mismos |
| CN104169304A (zh) | 2011-12-20 | 2014-11-26 | 阿达拉塔合伙有限公司 | 作为pcsk9抑制剂的单域抗体 |
| WO2013148284A1 (en) | 2012-03-29 | 2013-10-03 | Genentech, Inc. | Antibodies that bind to a pcsk9 cleavage site and methods of use |
| US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
| US20150140005A1 (en) | 2012-05-17 | 2015-05-21 | Cyon Therapeutics Inc. | Methods and Uses for Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Inhibitors |
| EP2861624A1 (en) * | 2012-06-15 | 2015-04-22 | F. Hoffmann-La Roche AG | Anti-pcsk9 antibodies, formulations, dosing, and methods of use |
| US20160039945A1 (en) * | 2013-03-15 | 2016-02-11 | Amgen Inc. | Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9 |
| CN105001336A (zh) * | 2014-04-18 | 2015-10-28 | 上海复旦张江生物医药股份有限公司 | Pcsk9拮抗剂 |
| WO2015200438A1 (en) * | 2014-06-24 | 2015-12-30 | Eleven Biotherapeutics, Inc. | High affinity antibodies against pcsk9 |
| CN104861071B (zh) * | 2015-04-27 | 2019-04-12 | 南京师范大学 | 针对pcsk9的全人源单克隆抗体的可变区基因及其应用 |
| CN105037554B (zh) * | 2015-06-12 | 2019-04-12 | 成都贝爱特生物科技有限公司 | 抗人pcsk9抗体的制备及其用途 |
-
2016
- 2016-12-20 EP EP16881019.0A patent/EP3398968B1/en active Active
- 2016-12-20 CN CN201680013073.1A patent/CN107406511B/zh active Active
- 2016-12-20 JP JP2018533863A patent/JP7032662B2/ja active Active
- 2016-12-20 MX MX2018007925A patent/MX2018007925A/es unknown
- 2016-12-20 RU RU2018125003A patent/RU2739208C2/ru active
- 2016-12-20 KR KR1020187020978A patent/KR102767973B1/ko active Active
- 2016-12-20 CA CA3009904A patent/CA3009904A1/en active Pending
- 2016-12-20 US US16/066,567 patent/US10793643B2/en active Active
- 2016-12-20 WO PCT/CN2016/111053 patent/WO2017114230A1/zh not_active Ceased
- 2016-12-20 BR BR112018013256-0A patent/BR112018013256A2/pt active Search and Examination
- 2016-12-20 AU AU2016382932A patent/AU2016382932B2/en active Active
- 2016-12-29 TW TW105143912A patent/TWI735499B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| US20190016825A1 (en) | 2019-01-17 |
| MX2018007925A (es) | 2018-08-29 |
| JP2019509254A (ja) | 2019-04-04 |
| KR20180093068A (ko) | 2018-08-20 |
| EP3398968A4 (en) | 2019-08-07 |
| AU2016382932A1 (en) | 2018-07-19 |
| KR102767973B1 (ko) | 2025-02-12 |
| CN107406511A (zh) | 2017-11-28 |
| TWI735499B (zh) | 2021-08-11 |
| BR112018013256A2 (pt) | 2018-12-11 |
| JP7032662B2 (ja) | 2022-03-09 |
| CA3009904A1 (en) | 2017-07-06 |
| RU2018125003A (ru) | 2020-02-03 |
| TW201725216A (zh) | 2017-07-16 |
| WO2017114230A1 (zh) | 2017-07-06 |
| RU2739208C2 (ru) | 2020-12-21 |
| EP3398968B1 (en) | 2024-06-12 |
| CN107406511B (zh) | 2021-01-19 |
| EP3398968A1 (en) | 2018-11-07 |
| HK1244828A1 (zh) | 2018-08-17 |
| US10793643B2 (en) | 2020-10-06 |
| AU2016382932B2 (en) | 2022-12-08 |